The effect of Percutaneous embolization in patients with symptomatic liver hemangiomas
Phase 2
Recruiting
- Conditions
- iver symptomatic hemangioma.Haemangioma, any siteD18.0
- Registration Number
- IRCT20130812014333N154
- Lead Sponsor
- Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
A giant hepatic hemangioma with clear margins
The number of platelets is more than 100,000
International Ratio Normalized less than 1/5
Exclusion Criteria
Patients with severe ascites
Improper position of the hemangioma
Patients with hepatic or renal impairment
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ltrasound volume. Timepoint: At the beginning of the study and 6 months after the end of the study. Method of measurement: Using the GE-Logic S6 ultrasound device.;Largest diameter of ultrasond. Timepoint: At the beginning of the study and 6 months after the end of the study. Method of measurement: Using the GE-Logic S6 ultrasound device.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bleomycin's anti-angiogenic effects in liver hemangioma embolization?
How does percutaneous bleomycin embolization compare to transarterial embolization for symptomatic liver hemangiomas?
Which biomarkers correlate with treatment response in IRCT20130812014333N154 liver hemangioma trials?
What adverse events are associated with bleomycin-based embolization in D18.0 hemangioma patients?
Are there synergistic combinations of bleomycin with anti-VEGF agents for hemangioma management?